TP53 and prostate cancer: Recently a compound has been developed which selectively inhibits the deubiquitinating activity of USP7 resulting in the stabilisation of p53 and increased apoptosis which may prove important for the treatment of aggressive prostate cancer which is associated with high USP7 levels [9, 28].